These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 1687131)

  • 1. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children.
    Ducharme FM; Ni Chroinin M; Greenstone I; Lasserson TJ
    Cochrane Database Syst Rev; 2010 May; (5):CD005535. PubMed ID: 20464739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma.
    Ducharme FM; Ni Chroinin M; Greenstone I; Lasserson TJ
    Cochrane Database Syst Rev; 2010 Apr; (4):CD005533. PubMed ID: 20393943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children.
    Ni Chroinin M; Greenstone I; Lasserson TJ; Ducharme FM
    Cochrane Database Syst Rev; 2009 Oct; (4):CD005307. PubMed ID: 19821344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regular treatment with salmeterol for chronic asthma: serious adverse events.
    Cates CJ; Cates MJ
    Cochrane Database Syst Rev; 2008 Jul; (3):CD006363. PubMed ID: 18646149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term safety and tolerability of double-dose salmeterol/fluticasone propionate in adult asthmatic patients.
    Adolfsson LE; Lundgren M; Tilling B; Jern S; Tyren C; Godwood A; Gor D
    Clin Drug Investig; 2005; 25(4):231-41. PubMed ID: 17523773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid.
    Walters EH; Gibson PG; Lasserson TJ; Walters JA
    Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD001385. PubMed ID: 17253458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease.
    Sovani MP; Whale CI; Tattersfield AE
    Drug Saf; 2004; 27(10):689-715. PubMed ID: 15350154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review.
    Salpeter SR
    Drugs Aging; 2004; 21(6):405-14. PubMed ID: 15084142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.
    Walters EH; Walters JA; Gibson PW
    Cochrane Database Syst Rev; 2002; 2002(4):CD003901. PubMed ID: 12519616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?
    Holimon TD; Chafin CC; Self TH
    Drugs; 2001; 61(3):391-418. PubMed ID: 11293649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diurnal variability--time to change asthma guidelines?
    Reddel H; Jenkins C; Woolcock A
    BMJ; 1999 Jul; 319(7201):45-7. PubMed ID: 10390464
    [No Abstract]   [Full Text] [Related]  

  • 12. Dose-response of inhaled drugs in asthma. An update.
    Clark DJ; Lipworth BJ
    Clin Pharmacokinet; 1997 Jan; 32(1):58-74. PubMed ID: 9012556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease.
    Grove A; Lipworth BJ; Reid P; Smith RP; Ramage L; Ingram CG; Jenkins RJ; Winter JH; Dhillon DP
    Thorax; 1996 Jul; 51(7):689-93. PubMed ID: 8882074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group.
    Lundback B; Rawlinson DW; Palmer JB
    Thorax; 1993 Feb; 48(2):148-53. PubMed ID: 8493629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long- versus short-acting beta 2-agonists. Implications for drug therapy.
    Boulet LP
    Drugs; 1994 Feb; 47(2):207-22. PubMed ID: 7512898
    [No Abstract]   [Full Text] [Related]  

  • 16. Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.
    Brogden RN; Faulds D
    Drugs; 1991 Nov; 42(5):895-912. PubMed ID: 1723379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease.
    Dahl R; Earnshaw JS; Palmer JB
    Eur Respir J; 1991 Nov; 4(10):1178-84. PubMed ID: 1687131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group.
    Britton MG; Earnshaw JS; Palmer JB
    Eur Respir J; 1992 Oct; 5(9):1062-7. PubMed ID: 1426215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group.
    Boyd G
    Eur Respir J; 1995 Sep; 8(9):1494-8. PubMed ID: 8575574
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.